Payment overview · 2025
General Payments
$1,618.50
80 reported records · 14 companies
Healthcare provider profile · identity verified
Cluny Lefevre, DO
Allopathic & Osteopathic Physicians|Family Medicine · NEW YORK, NY · NPI 1477505147
Verified facts
What the public records show
CMS Open Payments records show Cluny Lefevre, DO received $1,618.50 in general payments during 2025 across 80 reported records.
ViiV Healthcare Company accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $411.43 | 25.4% | 14 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $287.16 | 17.7% | 18 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $246.81 | 15.2% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $193.25 | 11.9% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $148.98 | 9.2% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.10 | 4.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.64 | 4.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.45 | 4.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.97 | 1.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.95 | 1.9% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $27.08 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.17 | 1.0% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $14.36 | 0.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.15 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,618.50 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $411.43 | 14 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $246.81 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $193.25 | 11 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $151.16 | 9 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $136.00 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $128.76 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $111.63 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $65.64 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.99 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.99 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $32.52 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $29.97 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.95 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 225 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 192 | 56 |
| Omeprazole | Omeprazole | 179 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 147 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 134 | 25 |
| Metformin Hcl | Metformin Hcl | 131 | 34 |
| Simvastatin | Simvastatin | 129 | 35 |
| Gabapentin | Gabapentin | 111 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 22 |
| Ibuprofen | Ibuprofen | 106 | 23 |
| Lisinopril | Lisinopril | 103 | 25 |
| Meclizine Hcl | Meclizine Hcl | 99 | 28 |
| Ozempic | Semaglutide | 81 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 77 | 14 |
| Montelukast Sodium | Montelukast Sodium | 75 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 16 |
| Meloxicam | Meloxicam | 61 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 16 |
| Linzess | Linaclotide | 59 | suppressed |
| Losartan Potassium | Losartan Potassium | 58 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 51 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 50 | 11 |
| Alendronate Sodium | Alendronate Sodium | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 11 |
| Enalapril Maleate | Enalapril Maleate | 47 | suppressed |
| Furosemide | Furosemide | 46 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 45 | suppressed |
| Rybelsus | Semaglutide | 45 | suppressed |
| Alprazolam | Alprazolam | 43 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 41 | 12 |
| Carvedilol | Carvedilol | 40 | 11 |
| Farxiga | Dapagliflozin Propanediol | 38 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 13 |
| Famotidine | Famotidine | 34 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | suppressed |
| Naproxen | Naproxen | 31 | 15 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Terconazole | Terconazole | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,618.50 · 80 records | ViiV Healthcare Company | ABRYSVO, APRETUDE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, GLYCATE, IBSRELA, JARDIANCE, MOUNJARO, NURTEC ODT, PREVNAR 20, RELISTOR, RELTONE 200 MG, RELTONE 400 MG, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, XIFAXAN, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error